L 131
Alternative Names: L-131Latest Information Update: 15 Jan 2024
At a glance
- Originator Lobe Sciences
- Class Anxiolytics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders
Most Recent Events
- 02 Jan 2024 Lobe Sciences plans a phase I trial in Anxiety disorders (PO) in the second half of 2024 (Lobe Sciences pipeline, January 2024)
- 02 Jan 2024 Preclinical trials in Anxiety disorders in Canada (PO) (Lobe Sciences pipeline, January 2024)
- 02 Jan 2024 Lobe Sciences plans to apply for the priority review status to US FDA in USA for Anxiety Disorders(Lobe Sciences pipeline, January 2024)